Format

Send to

Choose Destination
Cancer Lett. 2016 Apr 28;374(1):31-43. doi: 10.1016/j.canlet.2016.01.050. Epub 2016 Feb 6.

Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy.

Author information

1
Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Republic of Korea.
2
Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Republic of Korea. Electronic address: sehoonkim@kist.re.kr.

Abstract

Nanocarriers (NCs) are a group of nano-sized vehicles devised to deliver drugs to targeted malignant tissues or organs that provide remarkably improved targeting efficiency and therapeutic efficacy for cancer therapy. A variety of NCs have been developed to accommodate appropriate loading and release of drugs with a wide spectrum of chemical and physical characteristics. In addition, physicochemical modifications to the surface or interior of NCs allow for modulation of pharmacokinetic features reflecting clinical demands. However, cancer-related mortality is still high and drug-mediated cancer treatment remains a challenging research field despite the remarkable advances in targeting efficiency and therapeutic efficacy resulting from NCs. In this review, we focus on typical approaches and recent trends in NC-mediated drug delivery systems and their potential for targeted cancer therapy.

KEYWORDS:

Cancer therapy; Combination therapy; Drug delivery; Nanocarrier; Stimuli-activated therapy

PMID:
26854717
DOI:
10.1016/j.canlet.2016.01.050
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center